Long-term effects of 1,25(OH)2D3 on clinical and biochemical derangements of divalent ions in dialysis patients.
作者信息
Goldstein D A, Malluche H H, Massry S G
出版信息
Contrib Nephrol. 1980;18:42-54. doi: 10.1159/000403272.
PMID:7353379
Abstract
摘要
相似文献
1
Long-term effects of 1,25(OH)2D3 on clinical and biochemical derangements of divalent ions in dialysis patients.1,25-二羟维生素D3对透析患者二价离子临床及生化紊乱的长期影响
Contrib Nephrol. 1980;18:42-54. doi: 10.1159/000403272.
2
Clinical effects of 1,25-dihydroxyvitamin D3 in uremic patients with overt osteodystrophy.
Contrib Nephrol. 1980;18:29-41. doi: 10.1159/000403271.
3
[Use of 5,6-trans-25-OH-cholecalciferol in patients needing dialysis with florid renal osteopathy: therapeutic management and treatment results].
Verh Dtsch Ges Inn Med. 1977;83:1307-10.
4
A skeletal mineralizing defect in dialysis patients: a syndrome resembling osteomalacia but unrelated to viatamin D.透析患者的骨骼矿化缺陷：一种类似骨软化症但与维生素D无关的综合征。
Contrib Nephrol. 1980;18:172-83. doi: 10.1159/000403285.
5
Effects of 6 months therapy with 1,25 (OH)2D3 on bone disease of dialysis patients.
Contrib Nephrol. 1980;18:98-104. doi: 10.1159/000403277.
6
An evaluation of 1 alpha-hydroxy-and 1,25-dihydroxyvitamin D3 in the treatment of renal bone disease.
Contrib Nephrol. 1980;18:12-28. doi: 10.1159/000403270.
7
Hemodialysis patients with a unique mineralizing defect unresponsive to 1,25-dihydroxycholecalciferol. Dialysis osteomalacic syndrome.患有独特矿化缺陷且对1,25 - 二羟胆钙化醇无反应的血液透析患者。透析性骨软化综合征。
Contrib Nephrol. 1980;18:162-71. doi: 10.1159/000403284.
8
Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.1,25-二羟维生素D3与24,25-二羟维生素D3在肾性骨营养不良长期治疗中的比较
Proc Eur Dial Transplant Assoc. 1980;17:543-7.
9
Use of 1,25(OH)2-vitamin D3 in prevention of renal osteodystrophy: preliminary observations.
Contrib Nephrol. 1980;18:147-51. doi: 10.1159/000403282.
10
Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.1,25(OH)₂D₃在肾性骨营养不良管理中的应用现状
Kidney Int. 1980 Oct;18(4):409-18. doi: 10.1038/ki.1980.154.
引用本文的文献
1
Association of Anabolic Effect of Calcitriol with Osteoclast-Derived Wnt 10b Secretion.骨化三醇的同化作用与破骨细胞衍生的 Wnt10b 分泌的关联。
Nutrients. 2018 Aug 25;10(9):1164. doi: 10.3390/nu10091164.
2
Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients.新千年第一个十年的肾性骨营养不良：对黑人和白人患者 630 例骨活检的分析。
J Bone Miner Res. 2011 Jun;26(6):1368-76. doi: 10.1002/jbmr.309.
3
Effects of treatment of renal osteodystrophy on bone histology.肾性骨营养不良的治疗对骨组织学的影响。
Clin J Am Soc Nephrol. 2008 Nov;3 Suppl 3(Suppl 3):S157-63. doi: 10.2215/CJN.02500607.
4
Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis.接受维持性血液透析的无症状甲状旁腺功能亢进患者口服1,25-二羟基维生素D3与安慰剂的双盲试验。
Br Med J (Clin Res Ed). 1981 Jun 13;282(6280):1919-24. doi: 10.1136/bmj.282.6280.1919.
Zotero 插件